Cancer Translational Medicine

Review | Open Access

Vol.8 (2022) | Issue-3 | Page No: 76-86


Advances in Pathogenesis and Non-surgical Therapy of Cutaneous Basal Cell Carcinoma

Yichen Wu1, Jia Chen2*


1. Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China

2. Department of Dermatopathology, Shanghai Skin Disease Hospital, Shanghai, China

*Corresponding Author

Address for correspondence: Prof. Jia Chen, Department of Dermatopathology, Shanghai Skin Disease Hospital, No.1278 Baode Road, Jing'an District, Shanghai 200040, China. E-mail:

Important Dates  

Date of Submission:   18-May-2022

Date of Acceptance:   25-Jul-2022

Date of Publication:   29-Sep-2022


Basal cell carcinoma (BCC) is a low-grade malignant skin tumor originating from basal cells, which is closely related to UV radiation and tends to occur on the face. Fortunately, most of the tumors are localized and easily amenable to surgical resection. However, for those patients with specific areas of skin lesions and locally advanced as well as, in rare cases, metastatic BCC may pose a therapeutic challenge. Therefore, non-surgical treatment is needed as an important supplement or even the preferred option. In this review, we will outline the currently known pathogenesis and non-surgical therapy of BCC. With our understanding of the molecular basis of BCC, emerging targeted therapeutics such as Hedgehog pathway inhibitors, photodynamic therapy, and combined therapy are offering new avenues for the non-surgical treatment of BCC.

Keywords: Basal cell carcinoma, pathogenesis, therapy


Basal cell carcinoma (BCC), also known as basal cell epithelioma, is the most common nonmelanoma skin cancer, accounting for 80% of cases.[1] A slowly growing tumor, BCC seldom metastasizes and has a benign evaluation, although some high-risk variants of BCC can lead to deadly results.[2] Currently, the preferred treatment plan for BCC is complete surgical resection. However, some patients are not suitable for this treatment due to age, health state, location of lesions, lesion generalization, and uncommon metastatic BCC, which can cause gradual disfigurement or even death. In recent years, many non-surgical treatments have emerged with further understanding of the pathogenesis of BCC. In this article, we discuss a brief overview of non-surgical therapies for BCC as well as emerging targeted therapeutics such as Hedgehog pathway inhibitors and immune modulators. These therapeutics have the potential to revolutionize the treatment of this common and important skin cancer.


Hedgehog signaling pathway

During early embryonic development, the Hedgehog (HH) signaling pathway contributes to the formation of the neural tube, musculoskeletal system, hematopoietic cells, teeth, and skin. The mammalian Hedgehog family includes the Sonic Hedgehog (SHH), India Hedgehog (IHH), and Desert Hedgehog (DHH). IHH regulates chondrogenic differentiation and DHH is important for spermatogenesis and development of the neural fasciculus of peripheral nerves. Within the skin, the SHH pathway is primarily responsible for stem cell maintenance and controlling the development of hair follicles and sebaceous glands.[3] It has been suggested that BCC originates from stem cells permanently settled in the parietal epidermis and upper part of the hair follicle funnel.[4] Both in nevus-like basal cell carcinoma syndrome (NBCCS) or in sporadic basal cell carcinoma, aberrant activation of the SHH pathway plays a key role in tumor initiation, progression, and recurrence. Sonic Hedgehog ligands, patched 1 (PTCH1), smoothened (SMO), and GLI (glioma associated oncogene protein) are the key components of this pathway. Normally, PTCH1 acts as a regulatory molecule, reducing HH signaling by inhibiting the translocation of SMO cilia. When SHH ligand binds to PTCH1, the PTCH1-SHH complex is degraded by lysosomes which de-represses SMO, upregulating the downstream signaling cascade via several proteins, including SUFU (suppressor of fused). This ultimately leads to the release of GLI protein family members such as GLI1 (glioma associated oncogene protein-1). The GLI1 translocates to the cell nucleus and triggers the transcription of HH-dependent target genes, leading to the development of BCC.[5] Some studies have found that, somatic PTCH1 mutations can occur upto 75% of the time. It is generally well-established that heterozygous germline deletion of the PTCH1 molecular mechanism leads to NBCCS/Gorlin syndrome. Shift mutations in PTCH2 can also lead to NBCCS.[6] In addition, activating SMO mutations have been reported in approximately 10% - 20% of BCCs, demonstrating that activating mutations in SMO can induce BCC by activating the HH signaling pathway.[7]


The second most frequent factor associated with BCC pathogenesis is the mutations of the TP53 gene. The role of the vital tumor suppressor protein p53, encoded in the TP53 gene, is involved in cell cycle arrest and activation of programmed death. Somatic mutations in TP53 are common in BCC. A study has shown that TP53 mutations were found in 17 of 42 BCCs (40%).[8] P53 enhances apoptosis via repressing the BCL2 and inhibiting SMO proteins in the HH pathway.[3],[9] TP53 can interact with and repress GLI though it is not a part of the Hedgehog pathway. Therefore, mutations in TP53 further enhance Hedgehog signaling in BCC. In a mouse model studying BCC pathogenesis, P53 loss increased SMO expression sensitizing epidermal keratinocytes to the oncogenic effects of PTCH1 deletion, which in turn led to the development of BCC.[10] In addition, P53 could also enhance P21 protein function, inhibiting tumor formation.

DNA and histone methylation

Epigenetics plays a crucial role in transcriptional regulation. The expression of genes involved in essential cellular pathways can be altered by the aberrant epigenetic organization.[11] In addition to the PTCH1 and TP53, data from both The Cancer Genome Atlas (TCGA)[12] and the Catalogue of Somatic Mutations in Cancer (COSMIC)[13] suggest that histone methyltransferases are also among the most commonly mutated genes. A recent study results showed an association between advanced BCC and the histone methyltransferase EZH2. They assessed the expression levels of EZH2 in 30 less aggressive BCC subtypes and 30 more aggressive subtypes. EZH2 expression was significantly higher in the more aggressive BCC than in the less aggressive BCC and was positively correlated with BCC aggressiveness.[14],[15] This result suggests that EZH2 could serve as a potential target for inhibiting BCC progression and that EZH2-associated epigenetic marker profiles could serve as histological markers of BCC aggressiveness.

Aberrant DNA methylation in association with abnormal gene expression is another hallmark of cancer. Brinkhuizen et al. tested the DNA methylation status, using MSP (methylation-specific polymerase) chain reaction, of 9 oncogenes and one oncogene promoter region in 112 BCC patients and 124 healthy controls. Results showed that SHH, adenomatous polyposis coli (APC), secreted frizzled-related protein 5 (SFRP5), and RAS-associated structural domain family 1 (RASSF1) genes were significantly hypermethylated in BCC.[16]

The Hippo-Yap signaling pathway

The Hippo pathway, which plays an essential role in tissue growth restriction, consists of a series of kinases. Dysfunctional regulation of the Hippo-Yap pathway has been reported in BCC from RNA sequencing research, with up-regulated YAP (Yes-associated protein) triggering proliferation of basal keratinocytes. LATS1 gene encodes one of the kinases in the Hippo pathway. Premature stop mutations in these LATS1 genes have been reported in 16% of BCC. Additionally, LATS2 gene (analog of LATS) mutations have been observed in 12% of tumors.[17]

MYCN/FBXW7 signaling

MYCN is a transcriptional activator, probably downstream of the HH pathway, involved in cell proliferation and differentiation.[17] Missense mutations have been detected in 30% of BCC, mainly within the MYC box1 region that interacts with FBXW7, a tumor suppressor, which triggers N-MYC ubiquitin degradation. But this is usually prevented by mutations in the box1 structural domain.[7]


The TERT gene encodes telomerase which is an enzyme that adds protective repeat sequences to telomeres.[18] Increasing telomere length immortalizes cells, prevents aging and allows excessive cellular replication that are characteristic features of 90% of malignant tumors, including BCC.[19]

DPH3-OXNAD1 bidirectional promotor

Bidirectional promoters of the DPH3 and OXNAD1 genes are shown to be the common sites of somatic mutations in BCC, with Typical UV-signature mutations observed in most of the BCC samples.[20] The DPH3 gene is required to produce diphthamide, a modified histidine residue in eukaryotic elongation factor 2 that helps maintain translation fidelity.[21]

Other possible driver genes

Other genes suggested as possible driver genes for BCC include PPP6C, STK19, KRAS, and PIK3CA. Additional genes found to be mutated at lower frequencies in BCC include RB1, KNSTRN, CASP8, RAC1, ARID1A, CSMD1/2, PREX2, GRIN2A, and NOTCH1/2.[7],[22] Whether these genes are the primary drivers of BCC development or just secondary mutations remains unclear.


Therapeutic options currently available have been divided into Surgical treatments, Systemic Therapy, Topical Therapy and Physical Therapy. Each method is elaborated here and Table 1 lists all the methods including their advantages and disadvantages.

Surgical treatments

The main surgical treatments include surgical excision and Mohs microsurgery (MMS). Surgical excision aims to resect tumors as completely as possible based on strict adherence to the contraindications and indications for surgery. Therefore, in addition to removing the periphery of the visible tumor border, standard surgery also requires the removal of a particular area of clinically uninvolved skin tissue. Since BCC occurs mainly on the head and face, excizing excessive skin tissue hinders repair of skin defects and negatively affects the patient's appearance.[23]

MMS is used to define the degree of tumor infiltration and microscopic resection. It is not appropriate for locally advanced and metastatic BCC or eyelid BCC due to the orbital soft tissues, even though it guarantees that no tumor cells remain at the cut edge and maximizes the preservation of normal tissues. Intraoperative frozen sections are prone to false-negative results and do not ensure clean tumor resection, locally advanced and metastatic BCC requires radiation therapy or systemic therapy.[24] Recently, a Meta-analysis involving all the therapeutic options for BCC showed a recurrence rate of 3.2% at 5 years in patients treated with MMS and 5.2% with Surgical excision.[25] Surgical resection is highly invasive, especially when a local flap or implant reconstruction is recommended. Moreover, it tends to leave scars, cause hyperpigmentation and hypopigmentation, and cannot achieve the desired cosmetic results. As for small primary BCC of the trunk or extremities lacking invasive clinical or histopathological features, MMS is not indicated because other procedures have similar efficacy, whereas MMS is time-consuming, expensive, and requires higher equipment requirements.[26]

Non-surgical treatments

Prior treatment modalities emphasized on platinum-based therapies. Single or combination platinum-containing agents are effective in advanced BCC. Case reports of patients with BCC have shown responses to the combination of platinum-containing agents such as cisplatin and paclitaxel, cisplatin and vincristine, cisplatin and cyclophosphamide, carboplatin and paclitaxel.[27],[28] In cisplatin-based treatment, the overall response rates of metastatic BCC are as high as 77%.[27] However, most patients eventually relapse and die because of this disease. Thus, some emerging small-molecule inhibitors that showed good efficacy and high security have been the focus of recent therapeutic advancements. In the following portion, we make an introduction about them in detail.[29]

Hedgehog signaling pathway inhibitors

Hedgehog signaling pathway inhibitors can effectively target the treatment of locally advanced BCC and metastatic BCC, especially small molecule-targeted SMO inhibitors, which reflect better anti-BCC effects.

Small molecule-targeted SMO inhibitors

Vismodegib and Sonidegib are currently approved for the treatment of BCC, while BMS-833923, LY2940680, Saridegib, and TAK-441 are still in clinical development.[30] Vismodegib is a small molecule drug that binds to SMO and inhibits its activity, thereby inhibiting the GLI2 transcription factor and therefore blocking the expression of the HH signaling pathway, making it effective for the treatment of BCC. In phase III clinical study of Vismodegib in BCC,150 mg orally once daily for 28 d as a treatment cycle, in 482 patients who met the criteria for efficacy evaluation in solid tumors, 155 patients (32%) showed a complete response, 158 patients (33%) had a partial response and 128 patients (27%) with stable disease. It is shown that Vismodegib could be a novel treatment option for locally invasive and metastatic BCC.[31] According to another study by Tang et al. who divided 41 patients with NBCS into two groups, Vismodegib group and placebo group, Vismodegib resulted in tumor shrinkage of BCC in NBCS and suppression of neoplastic BCC at the same time.[32]

Sonidegib has been approved by both the EMA and FDA for patients who experienced a relapse after surgery or radiation therapy for locally advanced BCC or were not candidates for these treatments.[33] In a multicenter, randomized, double-blind phase II trial, 230 subjects were randomized into Sonidegib 200 mg group (i.e., 79 on oral Sonidegib 200 mg daily) and the Sonidegib 800 mg group (i.e., 151 on oral Sonidegib 800 mg daily), of whom 194 were patients with locally advanced BCC and 36 were patients with metastatic BCC. Results showed that 43% of patients taking 200 mg orally and 38% of those taking 800 mg achieved an objective response, while the response rates in the metastatic BCC group were 15% and 17%, respectively.[34] Thus, compared to advanced BCC, the efficiency of Sonidegib was lower in metastatic BCC. In Phase I clinical study of Saridegib, similar results were observed.[35] Metastatic BCC cannot be treated as effectively as primary BCC due to a low PTCH1 mutation and has a different phenotype and genotype. New therapeutic approaches are therefore needed to treat this disease.[36]  

Small molecule-targeted SMO inhibitors have great promise for the treatment of BCC. But at the same time, some limitations exist as well. (I) Drug resistance. Most patients will develop resistance within a few months. (II) Metastatic BCC is relatively insensitive to Hedgehog inhibitors, and more new targets need to be identified. (III) Inhibition of the HH pathway by SMO may lead to the activation of another pathway and the creation of other tumors. In a study of 104 patients with advanced BCC treated with Vismodegib, squamous cell carcinoma occurred in 11% of patients, which may be related to this mechanism.[37] (IV) In some cases, adverse effects such as muscle spasms, rheumatic pain, alopecia, fatigue, and weight reduction may occur during treatment, which should be managed and prevented in the clinic.

Other Hedgehog signaling pathway inhibitors      

Pathway inhibitors that target the SMO protein are being developed and used in the clinic. In spite of this, the development of resistance caused by point mutations in SMO limits the therapeutic application of SMO inhibitors. Moreover, different mechanisms exist which activate HH signaling in cancer cells that bypass SMO. Therefore, identifying the HH inhibitors that modulate proteins as potential targets while avoiding the problem of resistance is of great interest. Studies have focused on antagonists of GLI1, a transcription factor downstream of the HH pathway. A recent study showed that Pipinib reduces the incidence of disease by selectively inhibiting phosphatidylinositol 4-kinase IIIβ (PI4KB) and suppressing GLI-mediated transcription and expression of the HH target genes, PTCH1 and GLI1, by blocking SMO localization to cilia. Thus, inhibition of PI4KB followed by a reduction in phosphatidyl‐4‐phosphate levels could serve as an alternative approach to inhibit SMO function and HH signaling.[38]

Inhibition of the downstream effector GLI by arsenic trioxide and the antifungal drug itraconazole is also considered a weak HH pathway inhibitor. An open-label, exploratory phase II trial of oral itraconazole for the treatment of BCC by Kim et al. Found that itraconazole reduced cell proliferation by 45%, HH pathway activity by 65%, and tumor area by 24%. Another study reported the application of standard-dose or reduced dose of Vismodegib (150 mg, 1-2 times a week) in combination with itraconazole for 2 cases of recurrent facial BCC, both showing clinical remission after 16 months of follow-up.[39] Further, combination therapy may reduce the dose of HH pathway inhibitors and reduce adverse effects, which are still being explored.[40] A preliminary study of five patients with metastatic BCC treated with the combination of arsenic trioxide and itraconazole showed a reduction in GLI1 mRNA levels by 75% from baseline after 3 months of treatment. However, there was no significant reduction in tumor size.[41] In addition, Sohn et al. showed results from a trial of topical itraconazole for basal cell nevus syndrome that, at the maximum soluble concentration of 0.7%, itraconazole gel did not reduce GLI1 mRNA levels or the size of BCC tumors. Nevertheless, this trial did not rule out that other formulations of itraconazole at higher concentrations could be more effective. Therefore, the efficacy of topical itraconazole in BCC needs to be further investigated.[42]

Programmed cell death receptor 1 (PD-1) inhibitor    

Another potential target for the treatment of BCC is immunotherapy since skin immune cells have an anti-tumor effect, and PD-1 is an immune checkpoint receptor located on lymphocytes, which, when activated by PD-1 ligands, triggers downregulation of immune function, leading to a decrease in immune tolerance. Markers predicting the effectiveness of PD-1 inhibitor therapy include programmed death factor ligand-1 (PD-L1) amplification in tumor cells and high tumor mutational burden (TMB), both of which are met in BCC. BCC has one of the highest mutational burdens of any human malignancy. In general, tumors with a high mutational burden are more responsive to PD-1 blockade.[43] Cemiplimab is a monoclonal antibody drug against the PD-1 target monoclonal antibody drug.[44] In an open-label, multi-center, single-arm, phase 2 trial, 84 patients with a histologically confirmed diagnosis of locally advanced basal cell carcinoma (Intolerant to previous HHI therapy or having no better than stable disease after 9 months on HHI therapy) were treated with intravenous infusions of Cemiplimab 350 mg over 30 minutes every 3 weeks for up to 93 weeks or until progression or unacceptable toxicity. This study demonstrated the safety and effectiveness of Cemiplimab as systemic therapy for locally advanced BCC and is the first immunotherapy drug for patients with locally advanced BCC after HHI therapy or for whom HHIs are not appropriate.[45] The recommended dose of Cemiplimab is 350 mg intravenously over 30 minutes every 3 weeks. Other PD-1 inhibitors, such as pembrolizumab, showed an objective response rate of 38% after 18 weeks in a study of 16 patients with advanced BCC.[46]

mTOR signaling pathway inhibitor

The mammalian target of rapamycin (mTOR) is a serine/threonine-protein kinase closely associated with cell growth, metabolism, and aging. It acts through two signaling complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Studies have shown that the mTOR pathway is highly expressed in BCC.[47] HH signals crossed over mTOR via SOX9 and showed that the SOX9-mTOR axis is a target protein downstream of SMO that enhances tumor clearance in BCC patients.[48] Therefore, drugs targeting mTOR have a therapeutic effect on progressive BCC. For example, Everolimus (mTORC1 inhibitor), an immunosuppressive agent and a proliferation signal inhibitor, targets mTOR exhibits substantial anti-neoplastic activity, principally against BCCs. Oral daily dose of 1.5 - 3 mg for 12 weeks or longer induces partial to complete BCC regression.[49]

Topical therapy


Imiquimod is a non-nucleoside heterocyclic amine drug, a small molecule immunomodulator that stimulates the body's immune system to recognize viral infections and tumors by inducing the body to produce cytokines such as IFN-α, TNF-α, and IL-12, ultimately eliminating the associated lesions.[50] Williams et al. conducted a randomized controlled study comparing standard surgical and imiquimod treatments. The absolute response rate for topical imiquimod was 83% at 5 years. Although clearly inferior to the 98% for excisional surgery, the cosmetic effect of imiquimod was outstanding compared to the surgical approach.[51] Karabulut et al. reported results from three patients treating large nodular BCC at the medial canthal area with 5% imiquimod cream, applied topically once daily, five times a week for 12 weeks, with no recurrence of the tumor at 3 years of follow-up after treatment.[52] Therefore, Imiquimod could serve as an alternative to surgical treatment in some specific sites.


5-Fluorouracil (5-FU) is a pyrimidine analogue. The 5-FU metabolites get incorporated into DNA and RNA as faulty building blocks, thus inhibiting the activity of thymidylate synthase. These mechanisms lead to the inhibition of cell growth and apoptosis. Since these mechanisms are especially effective in tissues with high proliferation rates, there is a certain "bias" against malignant cells. The FDA has approved topical 5-FU for the treatment of superficial BCC and actinic keratoses. A study in 2013 assessing the effectiveness of photodynamic therapy compared with imiquimod or fluorouracil in patients with superficial BCC, showed that the treatment success rate of 72.8% for photodynamic, 80.1% for 5% fluorouracil, and 83.4% for imiquimod at 5 years.[53] In general, this trial demonstrated that from topical imiquimod could be a viable option for the treatment of superficial BCC.

Physical therapy

5-aminolevulinic acid photodynamic therapy

Photodynamic therapy uses visible light to activate photosensitizers 5-aminolevulinic acid or benzoporphyrin derivatives. These photosensitizers produce cytotoxic reactive oxygen species (ROS) through protoporphyrin IX, an intracellular reactive oxygen product, that gets activated by visible light after accumulation in the organelle cell membrane, leading to tumor cell damage and death. It also exerts its effects by indirectly destroying tumor blood vessels and triggering immune responses.[54],[55] Expert consensus on the clinical application of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) as a clinical treatment for superficial basal cell carcinoma and nodular basal cell carcinoma that is not deeply invasive (< 2 mm). Zou et al. performed a meta-analysis comparing the efficacy and recurrence rates of PDT and surgery in 596 cases of nodular BCC, observing that PDT and surgery were comparable in terms of complete remission rates, however, an increased cumulative probability of recurrence was found for PDT compared to surgery.[56] Liu et al. divided 80 BCC into 2 groups, the control group underwent surgery alone while the observation group was treated with ALA-PDT combined with surgery.[57] The 1-year recurrence rate for the combined therapy group was 0 which also demonstrated a better long-term efficacy. In conclusion, ALA-PDT provides the advantage of specifically eliminating tumor cells while causing less damage to adjacent normal tissues, with equivalent efficacy to surgical therapy and better cosmetic results. However, combined therapy is recommended in clinical practice for improved treatment efficacy.[58]


Clinically, radiotherapy kills BCC tumors using superficial X-rays. Where surgical excision is not an option (medically/technically inoperable), radiotherapy offers an excellent alternative. Compared with surgical treatment, its advantages lie in killing tumor cells, preserving the shape and function of surrounding normal tissues without leaving scars, and having broad clinical application prospects. However, Radiotherapy may cause skin atrophy, capillary dilation, and depigmentation or pigmentation in the radiated field.[59] The 5-year cure rates according to a meta-analysis were 83% - 95% for radiation therapy.[60] Shan et al. treated 14 BCC patients with superficial X-rays, at a total dose of 45.6 - 53.2 Gy. The results showed that fourteen lesions in 14 patients disappeared, with no relapse after 2 years of follow-up. The main adverse effects were radiodermatitis and ulceration of the lesions, which disappeared within 1 month.[61] Superficial X-ray radiation therapy for BCC has a low recurrence rate, which is an ideal method for patients who are not suitable for surgical treatment. Furthermore, the efficacy of radiotherapy is linked to the extent of radiation and therefore the scope of radiotherapy should be strictly controlled. It is reported that small, low-risk BCC should be treated with a radiation field margin of 0.5 cm beyond the clinically apparent tumor, while high-risk BCC should be treated with wider margin of 1 to 1.5 cm.[62] Therefore, radiotherapy boundaries should be evaluated and paid attention to prevent side effects. For patients with advanced, aggressive facial BCC, radiation therapy may be given priority. Radiation therapy is contraindicated in Gorlin-Goltz syndrome since it induces secondary tumors. Different radiotherapy techniques have been developed to date, such as external beam radiotherapy and superficial brachytherapy. The choice between them has to consider many factors: tumor size, location, and infiltration depth.[63]


Electrochemotherapy (ECT) is a technique used to ablate malignant tumors by temporarily permeabilizing cells after exposing them to a brief pulsed electric field in combination with low doses of chemotherapeutics. The cell membrane gets temporarily destabilized by the local application of the electrical pulse leading to pore formation on the cell surface and allowing passive diffusion of drugs that are present locally to enter the cell. The National Institute for Health and Clinical Excellence in the United Kingdom deemed that ECT was a relatively safe treatment for primary BCC due to its simplicity of operation and less damage to surrounding normal tissues. A prospective randomized controlled trial was conducted by Clover et al. to compare the effectiveness of electrochemotherapy in combination with surgery for primary BCC.[64] After 60 days of treatment, all the lesions treated with ECT responded except for 8/69 (12%) who needed a second treatment to ensure a complete response. All patients who underwent surgical treatment showed complete histological clearance after primary excision, except two patients requiring a further wider excision. Five years after surgery, there were 5 recurrences in the ECT group and one recurrence in the surgery group. The overall complete response rate in the surgical group was 39/40 (97.5%). Another clinical trial evaluating the effectiveness of ECT in head and neck tumors, including BCC, showed that it was the best choice for small, primary, and early-stage tumors.[65] In conclusion, ECT can be an effective adjunct to surgical treatment of BCC, with reasonable durable response rates.

Combined therapy

Commonly used combination therapies include photodynamic combined with imiquimod, surgical combined with drug, radiation therapy or ALA-PDT.[66],[67] The laser immunotherapy (LIT), a combination of laser and immunotherapeutic agents, has recently been reported to have multiple potential advantages, including enabling topical delivery of immunological agents, as well as laser-based amplification of immunotherapeutic agents. Studies on LIT show direct anti-tumor effects as well as systemic adaptive immunity which is characterized by prevention of tumor recurrence and regression in distant untreated tumors. These findings imply that LIT can be used as adjuvant therapy for BCC patients who have failed to respond to single laser therapy or immunotherapy. Nevertheless, LIT remains an experimental strategy and further research in the field is warranted.[68] In addition, radiation combined with herbal medicine has also achieved progress. Zhang et al. showed that the Integrated Chinese and Western medicine, where they combined CO2 with Chinese herbal medicine to treat BCC, was superior to laser treatment alone.[69] External use of traditional Chinese medicine on laser wounds accelerates wound healing and reduce the proliferation of scarring since they are known to resolve decay and regenerat muscle, clears heat and detoxification and acts as anti-cancer agents. It enables to kill residual tumor cells, even improves the healing rate, and reduces the recurrence rate.[70]


Include gene therapy: gene therapy aims to correct or compensate for genetic defects by introducing an exogenous gene with the corresponding function to a cell with a functional defect. The occurrence of BCC is associated with multiple mutations, including K-ras, H-ras, N-myc, nm-23, and C-erb2. Numerous experimental studies have been conducted on gene therapy for BCC, and further research progress is expected. In addition, there are many other treatments like nanopulse therapy, cryotherapy, EGFR inhibitor Cetuximab, VEGFR inhibitor pazopanib, PI3K inhibitor Buparlisib (BKM120), and so on.

Table 1. Summary of therapies of Cutaneous Basal Cell Carcinoma and their advantages and disadvantages
Table 1. Summary of therapies of Cutaneous Basal Cell Carcinoma and their advantages and disadvantages


The molecular basis of BCC is complex, including genetic susceptibility and multiple somatic mutations. Recent advances in sequencing technology have allowed us to better understand the mutated genes and implicated molecular pathways. The non-surgical treatments discussed in this article are also based on these insights gained over the past decade into the molecular pathogenesis of BCC. As our knowledge of the disease continues to improve, we look forward to more innovative treatments emerging.





There are no conflicts of interest.


Not applicable.



Alter M, Hillen U, Leiter U, Sachse M, Gutzmer R. Current diagnosis and treatment of basal cellcarcinoma. J Dtsch Dermatol Ges 2015; 13(9): 863-74; quiz 875.


Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol 2015; 17(7): 497-503.


Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, García-Rodrigo CG, Fargnoli MC. Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci 2017; 18 (11): 2485.


Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, Sotiropoulou PA. Blanpain C. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010; 12(3): 299-305.


Kilgour JM, Jia JL, Sarin KY. Review of the Molecular Genetics of Basal Cell Carcinoma: Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. Cancers (Basel) 2021; 13(15): 3870.


Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19 Suppl 2: S127-47.


Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G , Zoete V, Seplyarskiy VB, Sharpe  HJ, McKee T, Letourneau A, Ribaux PG, Popadin K, Basset-Seguin N, Chaabene RB, Santoni FA, Andrianova MA, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016; 48(4): 398-406.


Reifenberger J, Wolter M, Knobbe C B, Köhler B, Schönicke A, Scharwächter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G. Somatic mutations in the PTCH, SMOH, SUFUH and T P53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005; 152(1): 43-51.


Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark 2010; 9(1-6): 267-86.


Wang GY, Wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell 2011; 19(1): 114-24.


Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. Nature 2019; 571(7766): 489-99.


Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6(269): pl1.


Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, Jupe SC, Kok CY, Noble K, Ponting L, Ramshaw CC, Rye CE, Speedy HE, Stefancsik R, Thompson SL, Wang S, Ward S, Campbell PJ, Forbes SA. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res 2019; 47(D1): D941-7.


Rao RC, Chan MP, Andrews CA, Kahana A. EZH2, Proliferation Rate, and Aggressive Tumor Subtypes in Cutaneous Basal Cell Carcinoma. JAMA Oncol 2016; 2(7): 962-3.


Rao RC, Chan MP, Andrews CA, Kahana A. Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification? - a short report. Cell Oncol (Dordr) 2018; 41(6): 693-8.


Brinkhuizen T, van den Hurk K, Winnepenninckx VJ, de Hoon JP, van Marion AM, Veeck J, van Engeland M, van Steensel MA. Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components. PLoS One 2012; 7(12): e51710.


Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alborán IM, Olson JM, Eisenman  RN. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 2006; 66(17): 8655-61.


Stacey SN, Sulem P, Masson G, Gudjonsson SA,Thorleifsson G,Jakobsdottir M, Sigurdsson A, Gudbjartsson DF, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Scherer D, Hemminki K, Rudnai P, Gurzau E, Koppova K, Botella-Estrada R, Soriano V, Juberias P, Saez B, Gilaberte Y, Fuentelsaz V, Corredera C, Grasa M, Hoiom V, Lindblom A, Bonenkamp JJ, van Rossum MM, Aben KK, de Vries E, Santinami M, Di Mauro MG, Maurichi A, Wendt J, Hochleitner P, Pehamberger H, Gudmundsson J, Magnusdottir DN, Gretarsdottir S, Holm H, Steinthorsdottir V, Frigge ML, Blondal T, Saemundsdottir J, Bjarnason H, Kristjansson K, Bjornsdottir G, Okamoto I, Rivoltini L, Rodolfo M, Kiemeney LA, Hansson J, Nagore E, Mayordomo JI, Kumar R, Karagas MR, Nelson HH, Gulcher JR, Rafnar T, Thorsteinsdottir U, Olafsson JH, Kong A, Stefansson K. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 2009; 41(8): 909-14.


Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer 2017; 123(S11): 2104-17.


Denisova E, Heidenreich B, Nagore E, Rachakonda PS, Hosen I, Akrap I, Traves V, Garcia-Casado Z, Lopez-Guerrero JA, Requena C, Sanmartin O, Serra-Guillen C, Llombart B, Guillen C, Ferrando J, Gimeno E, Nordheim A, Hemminki K, Kumar R. Frequent DPH3 promoter mutations in skin cancers. Oncotarget 2015; 6(34): 35922-30.


Wang L, Shi Y, Ju P, Liu R, Yeo SP, Xia Y,Owlanj H,Feng Z. Silencing of diphthamide synthesis 3 (Dph3) reduces metastasis of murine melanoma. PLoS One 2012; 7(11): e49988.


Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014; 134(1): 213-20.


Jiang M. Application of Mohs microsurgery for treating head and face malignant tumors. Mod Med Health 2011; 27(14): 2113-5. (in Chinese)


Seidl-Philipp M, Frischhut N, Höllweger N, Schmuth M, Nguyen VA. Known and new facts on basal cell carcinoma. J Dtsch Dermatol Ges 2021; 19(7):1021-41.


Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2020; 11(11): CD003412.


Li YL, Zhang XG, Wei F, Lu FM, Li YP. The Latest Progress in Comprehensive Treatment of Non-melanoma Superficial Malignant Skin Tumors and Precancerous Lesions. Chin J Dermatol Venereol 2017; 31(5): 563-5. (in Chinese)


Salem P, Hall SW, Benjamin RS, Murphy WK, Wharton JT, Bodey GP. Clinical phase I-II study of cis-dichloro-diammineplatinum (II) given by continuous lv infusion. Cancer Treat Rep 1978; 62(10): 1553-5.


Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 1990; 26(1): 73-7.


Campione E, Di Prete M, Lozzi F, Lanna C, Spallone G, Mazzeo M, Cosio T, Rapanotti  C, Dika E, Gaziano R, Orlandi A, Bianchi L. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. Chemotherapy 2020; 65(1-2): 2-10.


Gao Z, Bao J, Shi S, Zhang X, Gao Y, Zhu T. Effect of mutations on drug resistance of smoothened receptor toward inhibitors probed by molecular modeling. Chemical Physics Letters 2020; 741: 137126.


Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L,Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS,Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015; 16(6): 729-36.


Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366(23): 2180-8.


Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol 2018; 29(11): 2192-9.


Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16(6): 716-28.


Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 2013; 19(10): 2766-74.


Laga AC, Schaefer IM, Sholl LM, French CA, Hanna J. Metastatic Basal Cell Carcinoma. Am J Clin Pathol 2019; 152(6):706-17.


Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017; 17(1): 332.


Kremer L, Hennes E, Brause A, Ursu A, Robke L, Matsubayashi HT, Nihongaki Y, Flegel  J , Mejdrová I, Eickhoff J, Baumann M, Nencka R, Janning P, Kordes S, Schöler HR, Sterneckert J, Inoue T, Ziegler S , Waldmann H. Discovery of the Hedgehog Pathway Inhibitor Pipinib that Targets PI4KIIIß. Angew Chem Int Ed Engl 2019; 58(46): 16617-28.


Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32(8): 745-51.


Yoon J. Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma. JAAD Case Rep 2020; 7: 107-9.


Ally MS, Ransohoff K, Sarin K, Atwood SX, Rezaee M, Bailey-Healy I, Kim J, Beachy  PA, Chang AL, Oro A, Tang JY, Colevas AD. Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol 2016; 152(4): 452-6.


Sohn GK, Kwon GP, Bailey-Healy I, Mirza A, Sarin K, Oro A, Tang JY. Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial. JAMA Dermatol 2019; 155(9): 1078-80.


Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell  B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9(1): 34.


Lipson EJ, Lilo MT, Ogurtsova A, Esandrio J, Xu H, Brothers P, Schollenberger M, Sharfman WH, Taube JM. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer 2017; 5: 23.


Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22(6): 848-57.


Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, Van der Bokke L, Pague A, Brotherton R, Rieger KE, Satpathy AT, Yost KE, Reddy S, Sarin K, Colevas AD. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol 2019; 80(2): 564-6.


Wei SS, Yan QW, Yan L, Qiu XW, Lai K, Xiao S, Mi XB. Expression of mTOR, Beclin 1 and LC3 in non-melanoma skin tumors. Chin J Gerontology 2021; 41(11): 2279-83. (in Chinese)


Kim AL, Back JH, Chaudhary SC, Zhu Y, Athar M, Bickers DR. SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas. J Invest Dermatol 2018; 138(8): 1716-25.


Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas. Future Oncol 2015; 11(22): 2997-3002.


Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J 2004; 10(1): 4.


Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PSJ. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial. J Invest Dermatol 2017; 137(3): 614-9.


Karabulut GO, Kaynak P, Ozturker C, Fazil K, Ocak OB, Taskapılı M. Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian J Ophthalmol 2017; 65(1): 48-51.


Arits AH, Mosterd K, Essers BA, Spoorenberg E, Spoorenberg E, Sommer A, De Rooij MJ, van Pelt HP, Quaedvlieg PJ, Krekels GA, van Neer PA, Rijzewijk JJ, van Geest AJ, Steijlen PM, Nelemans PJ, Kelleners-Smeets NW.Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14(7): 647-54.


Lucena SR, Salazar N, Gracia-Cazaña T, Zamarrón A, González S, Juarranz Á, Gilaberte Y. Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. Int J Mol Sci 2015; 16(10): 25912-33.


Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kędzierska E, Knap-Czop K, Kotlińska J,Michel O,Kotowski K,Kulbacka J.Photodynamic therapy-mechanisms, photosensitizers and combinations. Biomed Pharmacother 2018; 106: 1098-107.


Zou Y, Zhao Y, Yu J, Luo X, Han J, Ye Z, Li J, Lin H. Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. J Cosmet Dermatol 2016; 15(4): 374-82.


Liu Y, Liu DX, Gao L. Long-term observation of ALA-PDT combined with surgery in the treatment of skin basal cell. J Clin Experimental Med 2018; 17(4): 415-8. (in Chinese)


Chinese guidelines for clinical application of aminolevulinic acid-based photodynamic therapy in dermatology (2021 edition). Chin J Dermatol 2021;54(1):1-9.


Veness MJ, Delishaj D, Barnes EA, Bezugly A, Rembielak A. Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol) 2019; 31(11): 749-58.


Wiegell SR, Skødt V, Wulf HC. Daylight-mediated photodynamic therapy of basal cell carcinomas - an explorative study. J Eur Acad Dermatol Venereol 2014; 28(2): 169-75.


Shan XF, Yang BQ, Tian HQ, Zhang FR. Efficacy of superficial X-ray in the treatment of 27 patients with basal and squamous cell carcinoma. Chin J Leprosy Skin Dis 2018; 34(10): 577-9. (in Chinese)


Wilmas KM, Garner WB, Ballo MT, McGovern SL, MacFarlane DF. The role of radiation therapy in the management of cutaneous malignancies. Part II: When is radiation therapy indicated? J Am Acad Dermatol 2021; 85(3): 551-62.


Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, Bataille V, Marmol VD, Dummer R, Harwood CA, Hauschild A, Höller C, Haedersdal M, Malvehy J, Middleton MR, Morton CA, Nagore E, Stratigos AJ, Szeimies RM, agliaferri L, Trakatelli M, Zalaudek I, Eggermont A, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 2019; 118: 10-34.


Clover AJP, Salwa SP, Bourke MG, McKiernan J, Forde PF, O'Sullivan ST, Kelly EJ, Soden DM. Electrochemotherapy for the treatment of primary basal cell carcinoma; A randomised control trial comparing electrochemotherapy and surgery with five-year follow up. Eur J Surg Oncol 2020; 46(5): 847-54.


Bertino G, Sersa G, De Terlizzi F, Occhini A, Plaschke CC,Groselj A, Langdon C, Grau JJ, McCaul JA, Heuveling D, Cemazar M, Strojan P, de Bree R, Leemans CR, Wessel I, Gehl J, Benazzo M. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur J Cancer 2016; 63: 41-52.


Liao C, Zhang G, Wang P, Sun X, Wang X. Combination curettage and modified ALA-PDT for multiple basal cell carcinomas of the face and head. Photodiagnosis Photodyn Ther 2021; 35: 102393.


Rizzo JM, Segal RJ, Zeitouni NC. Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis Photodyn Ther 2018; 21: 58-62.


Omland SH, Wenande EC, Svane IM, Tam J, Olesen UH, Hædersdal M. Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma. Cancers (Basel) 2021; 13(21): 5405.


Zhang S, Song SL, Huang F, Liu MY, Wang YH. Clinical study of CO2 laser combined with traditional Chinese medicine for the treatment of basal cell carcinoma. J South Med Univ 2010; 30(2): 399-400. (in Chinese)


Zhang ZQ. Features of Chinese medicine treatment for skin cancer. Family & Traditional Chin Med 2002; 9(9): 20. (in Chinese)



This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact:


All claims made in this article are exclusively those of the writers, and do not necessarily reflect the views of their connected organizations, the publisher, editors, or reviewers. The publication does not guarantee or promote any product that may be evaluated in this article or any claim made by its producer.

Related Articles

TRAF Proteins In NSCLC: Analysis Of Data From The Public Database And Literature Review

Xuebing Li1, Yaguang Fan1, Hongli Pan1, Yang Li1, Limin Cao1, Zhenhua Pan1, Lingling Zu1, Fanrong Meng2, Mengjie Li3, Qinghua Zhou1, Xuexia Zhou4*


Research Progress of Cytokines and Their Receptors in Ovarian Cancer

Yuanwen Zhang1, Zhouman He1, Shiyun Liang1, Jian Yuan1, Huihui Ti1 *



Contribution Of Human Endogenous Retroviruses To Metastasis Of Solid Tumors

Nianbin Li1, Jing Wang2, Yaguang Fan2, Min Wang2, Chen Chen2, Ting Wang1*, Heng Wu2*



Role of PD-1/PD-L1 Inhibitors in the Treatment of Metastatic Lung Cancer

Yufei Chen1, Mei Zhong2, Zhenhua Pan2, Jun Chen2, Hongli Chen2, Fengjie Guo2, 3,*



Cytochrome P450 2C19 Polymorphisms are Associated with a High Risk of Esophageal Squamous Cell Carcinoma in Asian Populations: A Systematic Review and Meta-Analysis

Xuehan Gao1, Zhihong Qian2, Guige Wang1, Lei Liu1, Jiaqi Zhang1, Ke Zhao1, Mengxin Zhou1, Shanqing Li1*

Limb Arterial Embolism secondary to Myocardial Primary Light Chain Amyloidosis – A Case Report

Lei Ji1, Zhili Liu1, Yuehong Zheng1*

In situ Laser Fenestration to Reconstruct Three Supra Arch Branches for Recurrent Aortic Dissection after Replacement of the Ascending Aorta and Implantation of Stent Graft in the Descending Aorta: A Case Report

Li Yuan Niu1, Hai Xin1, Hao Fu Wang1*, Yue Wei Wang1*

Research progress in traditional Chinese medicine for the treatment of androgenic alopecia

Weiwei LI1, Chenghao Zhu2, Dandan Yang3, Yanhua YI1, Shuncai Liu1, Zhenyu Gong1*

Isolated Abdominal Wall Metastasis without Definitive Primary Lesion after Laparoscopic Cholecystectomy: A Case Report

La Zhang1, Ning Jiang2, Rui Liao1, Baoyong Zhou1*, Dewei Li3*

Analysis of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer based on TCGA database

Haiyang Jiang1#, Longguo Dai1#, Huijian Wang1#, Chongjian Zhang1, Yu Bai1, Ruiqian Li1, Jun Li1, Chen Hu1, Hongyi Wu1, Hong Yang1, Qilin Wang1, Pingting Chen2*

Diagnostic Biomarkers in Cerebrospinal Fluid in Primary Central Nervous System Lymphoma: A Protocol for Systematic Review and Meta-analysis

Lili Zhou1,2, Hai Yi1*, Dan Chen1, Qian Zhang1, Fangyi Fan1, Ling Qiu1, Nan Zhang1, Yi Su1

Updates on Molecular Markers for Gliomas

Jingyao Jie1, Weijuan Zhang2*

Peroxisome Proliferator-Activated Receptor-γ Agonists as New Targets of Lung Cancer Therapy

Shixiong Wei1*

Microcirculation Specialist Consensus on Diagnosis and Treatment of Superficial Varicose Veins of Lower Limbs

Wang Lei1, Zheng Yuehong1*

Anticoagulation might not be necessary for asymptomatic central venous catheter-related thrombosis in adults

Wei Zhang1, Zhi Xiang1, Qin Ma2, Chuanlin Zhang3, Yu Zhao1, Qining Fu1*

The Roles of microRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer

Jingya Gao1*, Li Liu2*

Lung Cancer Tumor Microenvironment: An Update on Recent Advances in Research

Guangda Yuan1, Bowen Hu1, Yong Yang1*

Quantified ADC Values and Attenuation Trends for Diagnosing Prostate Cancer with Multiple b Values MRI

Jing Hu1#, Jingying Bu1#,Zhe Wang2#, Zhengdan Su2, Xiaoxian Wang2, Haiyao Pi3, Diliang Li2, Zhaoyang Pu4, Xin Tian1*

Differential Expression of T-box Transcription Factor TBX19 Regulates the Progression of Hepatocellular Carcinoma

Guifang He1, Yanjiao Hu2, Fuguo Dong3, Changchang Liu1, Duo Cai1, Shihai Liu1*

Quercetin Inhibits the Proliferation and Migration of Pancreatic Adenocarcinoma by Targeting the Prognostic-related Gene MMP1 via Bioinformatics and Network Pharmacology

Zhenhua Zu1,2#, Zhongguo Zhu3#, Zhiyu Xia2, Hongrang Chen1*, Yongsheng Li1*

Huge Lung Fibroleiomyomatous Hamartoma in the Pleural Cavity – A Case report

Minghui Liu1#, Xin Li1#, Hongbing Zhang1, Fan Ren1, Ming Dong1, Chunqiu Xia1, Jun Chen1,2*

Increased Expression of IL-17A, IL-6, STAT3, TGF-β, and VEGF: Potential Biomarkers in Bladder Cancer?

Zishen Xiao1, Chengxia Bai1, Teng Zhao1, Jiayu Lin1, Lijuan Yang1, Jian Liu2, Zhenjiang Wang1, Ying Sun3,4, Yanbo Liu1*

Identification of NSD2 as a Potential Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma

Wei Zhao1#, Xinyu Xiao1#, Yu Gao1,2, Shanshan Liu3, Xiuzhen Zhang1, Changhong Yang1, Qiling Peng1, Ning Jiang2*, Jianwei Wang1*

Quercetin Inhibits Glioma Proliferation by Targeting CDK1 and CCNB1 - Bioinformatics and Network Pharmacology

Huaixu Li1#, Peng Gao1#, Haotian Tian1, Zhenyu Han2, Xingliang Dai1*, Hongwei Cheng1*

Selective Internal Radiation Therapy with Yttrium-90 Microspheres in Hepatocellular Carcinoma – Applications and recent advances

Wei Wang1, Dawei Xie1, Bing Li1, Minghao Chen1*

Irreversible Electroporation in Pancreatic Cancer – Applications and recent advances

Yuanyuan Sun1, Qian Li2, Jia Hu2, Yanfang Liu2*, Xiaosong Li2*

Prognostic Value of Bismuth Typing and Modified T‑stage in Hilar Cholangiocarcinoma

Shengen Yi, Xiongjian Cui, Li Xiong, Xiaofeng Deng, Dongni Pei, Yu Wen, Xiongying Miao

MicroRNAs are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma

Haibo Huang1, Junjiao Gu1, Shuna Yao1, Zhihua Yao1, Yan Zhao1, Qingxin Xia2, Jie Ma2, Ling Mai3, Shujun Yang1, Yanyan Liu1

Comparison of Intra-voxel Incoherent Motion Diffusion Magnetic Resonance Imaging and Apparent Diffusion Coefficient in the Evaluation of Focal Malignant Liver Masses

Jinrong Qu1, Xiang Li1, Lei Qin2, Lifeng Wang1, Junpeng Luo1, Jianwei Zhang1, Hongkai Zhang1, Jing Li1, Fei Sun3, Shouning Zhang1, Yanle Li1, Cuicui Liu1, Hailiang Li1

Extracting Breathing Signal Using Fourier Transform from Cine Magnetic Resonance Imaging

Jing Cai1,2, Yilin Liu2, Fangfang Yin1,2

Split End Family RNA Binding Proteins: Novel Tumor Suppressors Coupling Transcriptional Regulation with RNA Processing

Hairui Su1, Yanyan Liu2, Xinyang Zhao1

Thioredoxin-interacting Protein as a Common Regulation Target for Multiple Drugs in Clinical Therapy/Application

Pengxing  Zhang1, Xiaoling Pang2,3, Yanyang Tu1,4

Associations of Age and Chemotherapy with Late Skin and Subcutaneous Tissue Toxicity in a Hypofractionated Adjuvant Radiation Therapy Schedule in Post‑mastectomy Breast Cancer Patients

Mohammad Akram1, Ghufran Nahid1, Shahid Ali Siddiqui1, Ruquiya Afrose2

Monitoring of Disease Activity in Chronic Myeloid Leukemia‑chronic Phase Patients Treated with Indian Generic Veenat (NATCO) Imatinib Mesylate: A Tertiary Care Experience

Khushboo Dewan, Tathagat Chatterjee

Review of Cancer Immunotherapy: Application of Chimeric Antigen Receptor T Cells and Programmed Death 1/Programmed Death‑ligand 1 Antibodies

Tengfei Zhang1,2, Ling Cao1, Zhen Zhang1, Dongli Yue1, Yu Ping1, Hong Li1, Lan Huang1, Yi Zhang1,3,4,5

Systematic Review of MicroRNAs and its Therapeutic Potential in Glioma

Nan Liu1, Yanyang Tu2

The Involvement of p53‑miR‑34a‑CDK4 Signaling During the Development of Cervical Cancer

Huijun Zuo, Jieqi Xiong, Hongwei Chen, Sisun Liu, Qiaoying Gong, Fei Guo

Unusual Clinical Presentation of a Rare Type of Breast Malignancy: A Case Report and a Short Review of Literature

Nadeesha J. Nawarathna1, Navam R. Kumarasinghe1, Palitha Rathnayake2,
Ranjith J. K. Seneviratne1

Sweet’s Syndrome in Acute Lymphoblastic Leukemia with t (9:22)

Khushboo Dewan, Shailaja Shukla

Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma

Daoyuan Wang1, Tiejun Yang2, Yongqiang Zou1, Xinqiang Yang1

Recent Progress in Genetic and Epigenetic Profile of Diffuse Gastric Cancer

Zhengxi He1, Bin Li1,2

Strategies for Management of Spinal Metastases: A Comprehensive Review

Zhantao Deng, Bin Xu, Jiewen Jin, Jianning Zhao, Haidong Xu

Application and Perspectives of Traditional Chinese Medicine in the Treatment of Liver Cancer

Xia Mao, Yanqiong Zhang, Na Lin

Primary Hepatic Carcinoid Tumor: A Case Report and Literature Review

Yupeng Lei1, Hongxia Chen2, Pi Liu1, Xiaodong Zhou1

Expression Characteristics of miR‑10b in Nasopharyngeal Carcinoma

Gang Li, Yunteng Zhao, Jianqi Wang, Haoran Huang, Mengwen Zhang

An Update on Immunohistochemistry in Translational Cancer Research

Zonggao Shi, M. Sharon Stack

Promoter Methylated Tumor Suppressor Genes in Glioma

Yingduan Cheng1, Yanyang Tu2, Pei Liang3

Palliative Treatment of Malignant Pleural Effusion

Chenyang Liu1*, Qian Qian2*, Shen Geng1, Wenkui Sun1, Yi Shi1

Functional Perspective and Implications of Gene Expression by Noncoding RNAs

Xiaoshuang Yan1, Huanyu Xu2, Zhonghai Yan3

Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib

James Joseph Driscoll

miR‑505 Downregulates 6‑Phosphofructo‑2‑Kinase/ Fructose‑2,6‑Biphosphatase 4 to Promote Cell Death in Glioblastoma

Esther H. Chung, Hongwei Yang, Hongyan Xing, Rona S. Carroll, Mark D. Johnson

Utility of Fine Needle Aspiration Cytology in Diagnosing Bone Tumors

Sonal Mahajan1, Akash Arvind Saoji2, Anil Agrawal1

Histone H2A and H2B Deubiquitinase in Developmental Disease and Cancer

Demeng Chen1, Caifeng Dai2, Yizhou Jiang3

Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity

Qian Li1, Yanyang Tu1,2

Acute Lymphoblastic Leukemia with Normal Platelet Count

Khushboo Dewan, Kiran Agarwal

Galanin is a Novel Epigenetic Silenced Functional Tumor Suppressor in Renal Cell Carcinoma

Shengkun Sun1*, Axiang Xu1*, Guoqiang Yang1, Yingduan Cheng2


Selenium Dioxide Induced Apoptosis in Cervical Cancer Cells via Regulating Apoptosis-related Let-7a MicroRNA and Proteins

Sisun Liu1, Jieqi Xiong2, Ling Guo3, Min Xiu1,4, Feng He1,4, Yuanlei Lou5, Fei Guo6,7

Low Expression of Polo‑like Kinase 1 is Associated with Poor Prognosis in Liver Cancer

Weixia Li1, Kunpeng Liu1, Dechen Lin2, Xin Xu2, Haizhen Lu3, Xinyu Bi4, Mingrong Wang2

Extracorporeal Photopheresis for Steroid‑refractory Chronic Graft‑versus‑host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta‑Analysis

Runzhe Chen1, Baoan Chen1, Peter Dreger2, Michael Schmitt2, Anita Schmitt2

Glucans and Cancer: Historical Perspective

Petr Sima1, Luca Vannucci1, Vaclav Vetvicka2

Implications of Circadian Rhythm Regulation by microRNAs in Colorectal Cancer

Song Wu1, Andrew Fesler2, Jingfang Ju2

BCL2 Family, Mitochondrial Apoptosis, and Beyond

Haiming Dai1, X. Wei Meng2, Scott H. Kaufmann2

Quantum Dot‑based Immunohistochemistry for Pathological Applications

Li Zhou1, Jingzhe Yan2, Lingxia Tong3, Xuezhe Han4, Xuefeng Wu5, Peng Guo6

CD24 as a Molecular Marker in Ovarian Cancer: A Literature Review

Lu Huang1, Weiguo Lv2, Xiaofeng Zhao1

Etiological Trends in Oral Squamous Cell Carcinoma: A Retrospective Institutional Study

Varsha Salian, Chethana Dinakar, Pushparaja Shetty, Vidya Ajila

Effect of Irinotecan Combined with Cetuximab on Liver Function in Patients with Advanced Colorectal Cancer with Liver Metastases

Yan Liang1, Yang Li2, Xin Li3, Jianfu Zhao4

The Role of Precision Medicine in Pancreatic Cancer: Challenges for Targeted Therapy, Immune Modulating Treatment, Early Detection, and Less Invasive Operations

Khaled Kyle Wong1, Zhirong Qian2, Yi Le3

Targeting Signal Transducer and Activator of Transcription 3 for Colorectal Cancer Prevention and Treatment with Natural Products

Weidong Li1,2*, Cihui Chen3*, Zheng Liu2, Baojin Hua1

The Potential of Wnt Signaling Pathway in Cancer: A Focus on Breast Cancer

Mahnaz M. Kazi, Trupti I. Trivedi, Toral P. Kobawala, Nandita R. Ghosh

Imaging‑driven Digital Biomarkers

Enrico Capobianco

Target‑Matching Accuracy in Stereotactic Body Radiation Therapy of Lung Cancer: An Investigation Based on Four‑Dimensional Digital Human Phantom

Jing Cai1,2, Kate Turner2, Xiao Liang2, W. Paul Segars2,3, Chris R. Kelsey1, David Yoo1, Lei Ren1,2, Fang‑Fang Yin1,2

Downregulation of Death‑associated Protein Kinase 3 and Caspase‑3 Correlate to the Progression and Poor Prognosis of Gliomas

Ye Song, Tianshi Que, Hao Long, Xi’an Zhang, Luxiong Fang, Zhiyong Li, Songtao Qi

Hyaluronic Acid in Normal and Neoplastic Colorectal Tissue: Electrospray Ionization Mass Spectrometric and Fluor Metric Analysis

Ana Paula Cleto Marolla1, Jaques Waisberg2, Gabriela Tognini Saba2, Demétrius Eduardo Germini2, Maria Aparecida da Silva Pinhal1

Melanoma Antigen Gene Family in the Cancer Immunotherapy

Fengyu Zhu1, Yu Liang1, Demeng Chen2, Yang Li1

Combined Chronic Lymphocytic Leukemia and Pancreatic Neuroendocrine Carcinoma: A Collision Tumor Variation

Kaijun Huang1, Panagiotis J. Vlachostergios1, Wanhua Yang2, Rajeev L. Balmiki3

Antiproliferative and Apoptotic Effect of Pleurotus ostreatus on Human Mammary Carcinoma Cell Line (Michigan Cancer Foundation‑7)

Krishnamoorthy Deepalakshmi, Sankaran Mirunalini

Impact of Age on the Biochemical Failure and Androgen Suppression after Radical Prostatectomy for Prostate Cancer in Chilean Men

Nigel P. Murray1,2, Eduardo Reyes1,3, Nelson Orellana1, Cynthia Fuentealba1, Omar Jacob1

Carcinoma of Unknown Primary: 35 Years of a Single Institution’s Experience

Rana I. Mahmood1,2, Mohammed Aldehaim1,3, Fazal Hussain4, Tusneem A. Elhassan4,
Zubeir A. Khan5, Muhammad A. Memon6

Metformin in Ovarian Cancer Therapy: A Discussion

Yeling Ouyang1, Xi Chen2, Chunyun Zhang1, Vichitra Bunyamanop1, Jianfeng Guo3

The Progress in Molecular Biomarkers of Gliomas

Jing Qi1, Hongwei Yang2, Xin Wang2, Yanyang Tu1

Correlation between Paclitaxel Tc > 0.05 and its Therapeutic Efficacy and Severe Toxicities in Ovarian Cancer Patients

Shuyao Zhang1*, Muyin Sun2*, Yun Yuan3*, Miaojun Wang4*, Yuqi She1*, Li Zhou5, Congzhu Li5, Chen Chen1, Shengqi Zhang4

Identifying Gaps and Relative Opportunities for Discovering Membrane Proteomic Biomarkers of Triple‑negative Breast Cancer as a Translational Priority

Bhooma Venkatraman

The Molecular Mechanism and Regulatory Pathways of Cancer Stem Cells

Zhen Wang1, Hongwei Yang2, Xin Wang2, Liang Wang3, Yingduan Cheng4, Yongsheng Zhang5, Yanyang Tu1,2

Nanoparticle Drug Delivery Systems and Three‑dimensional Cell Cultures in Cancer Treatments and Research

Wenjin Shi1, Ding Weng2,3, Wanting Niu2,3

Choline Kinase Inhibitors Synergize with TRAIL in the Treatment of Colorectal Tumors and Overcomes TRAIL Resistance

Juan Carlos Lacal1, Ladislav Andera2

MicroRNA Regulating Metabolic Reprogramming in Tumor Cells: New Tumor Markers

Daniel Otero‑Albiol, Blanca Felipe‑Abrio

Biomarkers of Colorectal Cancer: A Genome‑wide Perspective

José M. Santos‑Pereira1, Sandra Muñoz‑Galván2

Nicotinamide Adenine Dinucleotide+ Metabolism Biomarkers in Malignant Gliomas

Manuel P. Jiménez‑García, Eva M. Verdugo‑Sivianes, Antonio Lucena‑Cacace

Patient-derived Xenografts as Models for Personalized Medicine Research in Cancer

Marco Perez, Lola Navas, Amancio Carnero

Genome‑wide Transcriptome Analysis of Prostate Cancer Tissue Identified Overexpression of Specific Members of the Human Endogenous Retrovirus‑K Family

Behnam Sayanjali1,2

Clinical Utility of Interleukin‑18 in Breast Cancer Patients: A Pilot Study

Reecha A. Parikh, Toral P. Kobawala, Trupti I. Trivedi, Mahnaz M. Kazi, Nandita R. Ghosh

Current and Future Systemic Treatment Options for Advanced Soft‑tissue Sarcoma beyond Anthracyclines and Ifosfamide

Nadia Hindi1,2, Javier Martin‑Broto1,2

The Genomic Organization and Function of IRX1 in Tumorigenesis and Development

Pengxing Zhang1, Hongwei Yang2, Xin Wang2, Liang Wang3, Yingduan Cheng4, Yongsheng Zhang5, Yanyang Tu1,2

Stem Cell‑based Approach in Diabetes and Pancreatic Cancer Management

Yi‑Zhou Jiang1, Demeng Chen2

Mutation Detection with a Liquid Biopsy 96 Mutation Assay in Cancer Patients and Healthy Donors

Aaron Yun Chen, Glenn D. Braunstein, Megan S. Anselmo, Jair A. Jaboni, Fernando Troy Viloria, Julie A. Neidich, Xiang Li, Anja Kammesheidt

The Application of Estrogen Receptor‑1 Mutations’ Detection through Circulating Tumor DNA in Breast Cancer

Binliang Liu, Yalan Yang, Zongbi Yi, Xiuwen Guan, Fei Ma

Circulating MicroRNAs and Long Noncoding RNAs: Liquid Biomarkers in Thoracic Cancers

Pablo Reclusa1, Anna Valentino1, Rafael Sirera1,2, Martin Frederik Dietrich3, Luis Estuardo Raez3, Christian Rolfo1

Exosomes Biology: Function and Clinical Implications in Lung Cancer

Martin Frederik Dietrich1, Christian Rolfo2, Pablo Reclusa2, Marco Giallombardo2, Anna Valentino2, Luis E. Raez1

Circulating Tumor DNA: A Potential Biomarker from Solid Tumors’ Monitor to Anticancer Therapies

Ting Chen1,2, Rongzhang He1,3, Xinglin Hu1,3,4, Weihao Luo1, Zheng Hu1,3, Jia Li1, Lili Duan1, Yali Xie1,2, Wenna Luo1,2, Tan Tan1,2, Di‑Xian Luo1,2

Novel Molecular Multilevel Targeted Antitumor Agents

Poonam Sonawane1, Young A. Choi1, Hetal Pandya2, Denise M. Herpai1, Izabela Fokt3,
Waldemar Priebe3, Waldemar Debinski1

Fish Oil and Prostate Cancer: Effects and Clinical Relevance

Pei Liang, Michael Gao Jr.

Stemness‑related Markers in Cancer

Wenxiu Zhao1, Yvonne Li2, Xun Zhang1

Autophagy Regulated by miRNAs in Colorectal Cancer Progression and Resistance

Andrew Fesler1, Hua Liu1, Ning Wu1,2, Fei Liu3, Peixue Ling3, Jingfang Ju1,3

Gastric Metastases Mimicking Primary Gastric Cancer: A Brief Literature Review

Simona Gurzu1,2,3, Marius Alexandru Beleaua1, Laura Banias2, Ioan Jung1

Possibility of Specific Expression of the Protein Toxins at the Tumor Site with Tumor‑specialized Promoter

Liyuan Zhou1,2, Yujun Li1,2, Changchen Hu3, Binquan Wang1,2

SKI‑178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models

Jeremy A. Hengst1,2, Taryn E. Dick1,2, Arati Sharma1, Kenichiro Doi3, Shailaja Hegde4, Su‑Fern Tan5, Laura M. Geffert1,2, Todd E. Fox5, Arun K. Sharma1, Dhimant Desai1, Shantu Amin1, Mark Kester5, Thomas P. Loughran5, Robert F. Paulson4, David F. Claxton6, Hong‑Gang Wang3, Jong K. Yun1,2

A T‑cell Engager‑armed Oncolytic Vaccinia Virus to Target the Tumor Stroma

Feng Yu1, Bangxing Hong1, Xiao‑Tong Song1,2,3

Real‑world Experience with Abiraterone in Metastatic Castration‑resistant Prostate Cancer

Yasar Ahmed1, Nemer Osman1, Rizwan Sheikh2, Sarah Picardo1, Geoffrey Watson1

Combination of Interleukin‑11Rα Chimeric Antigen Receptor T‑cells and Programmed Death‑1 Blockade as an Approach to Targeting Osteosarcoma Cells In vitro

Hatel Rana Moonat, Gangxiong Huang, Pooja Dhupkar, Keri Schadler, Nancy Gordon,
Eugenie Kleinerman

Efficacy and Safety of Paclitaxel‑based Therapy and Nonpaclitaxel‑based Therapy in Advanced Gastric Cancer

Tongwei Wu, Xiao Yang, Min An, Wenqin Luo, Danxian Cai, Xiaolong Qi

Motion Estimation of the Liver Based on Deformable Image Registration: A Comparison Between Four‑Dimensional‑Computed Tomography and Four‑Dimensional-Magnetic Resonance Imaging

Xiao Liang1, Fang‑Fang Yin1,2, Yilin Liu1, Brian Czito2, Manisha Palta2, Mustafa Bashir3, Jing Cai1,2

A Feasibility Study of Applying Thermal Imaging to Assist Quality Assurance of High‑Dose Rate Brachytherapy

Xiaofeng Zhu1, Yu Lei1, Dandan Zheng1, Sicong Li1, Vivek Verma1, Mutian Zhang1, Qinghui Zhang1, Xiaoli Tang2, Jun Lian2, Sha X. Chang2, Haijun Song3, Sumin Zhou1, Charles A. Enke1

Role of Exosome microRNA in Breast Cancer

Wang Qu, Ma Fei, Binghe Xu

Recent Progress in Technological Improvement and Biomedical Applications of the Clustered Regularly Interspaced Short Palindromic Repeats/Cas System

Yanlan Li1,2*, Zheng Hu1*, Yufang Yin3, Rongzhang He1, Jian Hu1, Weihao Luo1, Jia Li1, Gebo Wen2, Li Xiao1, Kai Li1, Duanfang Liao4, Di-Xian Luo1,5

The Significance of Nuclear Factor‑Kappa B Signaling Pathway in Glioma: A Review

Xiaoshan Xu1, Hongwei Yang2, Xin Wang2, Yanyang Tu1

Markerless Four‑Dimensional‑Cone Beam Computed Tomography Projection‑Phase Sorting Using Prior Knowledge and Patient Motion Modeling: A Feasibility Study

Lei Zhang1,2, Yawei Zhang2, You Zhang1,2,3, Wendy B. Harris1,2, Fang‑Fang Yin1,2,4, Jing Cai1,4,5, Lei Ren1,2

The Producing Capabilities of Interferon‑g and Interleukin‑10 of Spleen Cells in Primary and Metastasized Oral Squamous Cell Carcinoma Cells-implanted Mice

Yasuka Azuma1,2, Masako Mizuno‑Kamiya3, Eiji Takayama1, Harumi Kawaki1, Toshihiro Inagaki4, Eiichi Chihara2, Yasunori Muramatsu5, Nobuo Kondoh1

“Eating” Cancer Cells by Blocking CD47 Signaling: Cancer Therapy by Targeting the Innate Immune Checkpoint

Yi‑Rong Xiang, Li Liu

Glycosylation is Involved in Malignant Properties of Cancer Cells

Kazunori Hamamura1, Koichi Furukawa2

Biomarkers in Molecular Epidemiology Study of Oral Squamous Cell Carcinoma in the Era of Precision Medicine

Qing‑Hao Zhu1*, Qing‑Chao Shang1*, Zhi‑Hao Hu1*, Yuan Liu2, Bo Li1, Bo Wang1, An‑Hui Wang1

I‑Kappa‑B Kinase‑epsilon Activates Nuclear Factor‑kappa B and STAT5B and Supports Glioblastoma Growth but Amlexanox Shows Little Therapeutic Potential in These Tumors

Nadège Dubois1, Sharon Berendsen2, Aurélie Henry1,2, Minh Nguyen1, Vincent Bours1,
Pierre Alain Robe1,2

Suppressive Effect of Mesenchymal Stromal Cells on Interferon‑g‑Producing Capability of Spleen Cells was Specifically Enhanced through Humoral Mediator(s) from Mouse Oral Squamous Cell Carcinoma Sq‑1979 Cells In Vitro

Toshihiro Inagaki1,2, Masako Mizuno‑Kamiya3, Eiji Takayama1, Harumi Kawaki1, Eiichi Chihara4, Yasunori Muramatsu5, Shinichiro Sumitomo5, Nobuo Kondoh1

An Interplay Between MicroRNA and SOX4 in the Regulation of Epithelial–Mesenchymal Transition and Cancer Progression

Anjali Geethadevi1, Ansul Sharma2, Manish Kumar Sharma3, Deepak Parashar1

MicroRNAs Differentially Expressed in Prostate Cancer of African‑American and European‑American Men

Ernest K. Amankwah

The Role of Reactive Oxygen Species in Screening Anticancer Agents

Xiaohui Xu1, Zilong Dang2, Taoli Sun3, Shengping Zhang1, Hongyan Zhang1

Panobinostat and Its Combination with 3‑Deazaneplanocin‑A Induce Apoptosis and Inhibit In vitro Tumorigenesis and Metastasis in GOS‑3 Glioblastoma Cell Lines

Javier de la Rosa*, Alejandro Urdiciain*, Juan Jesús Aznar‑Morales, Bárbara Meléndez1,
Juan A. Rey2, Miguel A. Idoate3, Javier S. Castresana

Cancer Stem‑Like Cells Have Cisplatin Resistance and miR‑93 Regulate p21 Expression in Breast Cancer

Akiko Sasaki1, Yuko Tsunoda2, Kanji Furuya3, Hideto Oyamada1, Mayumi Tsuji1, Yuko Udaka1, Masahiro Hosonuma1, Haruna Shirako1, Nana Ichimura1, Yuji Kiuchi1

The Contribution of Hexokinase 2 in Glioma

Hui Liu1, Hongwei Yang2, Xin Wang3, Yanyang Tu1

The Mechanism of BMI1 in Regulating Cancer Stemness Maintenance, Metastasis, Chemo‑ and Radiation Resistance

Xiaoshan Xu, Zhen Wang, Nan Liu, Pengxing Zhang, Hui Liu, Jing Qi, Yanyang Tu

A Multisource Adaptive Magnetic Resonance Image Fusion Technique for Versatile Contrast Magnetic Resonance Imaging

Lei Zhang1,2, Fang‑Fang Yin1,2,3, Brittany Moore1,2, Silu Han1,2, Jing Cai1,2,4

Senescence and Cancer

Sulin Zeng1,2, Wen H. Shen2, Li Liu1

The “Wild”‑type Gastrointestinal Stromal Tumors: Heterogeneity on Molecule Characteristics and Clinical Features

Yanhua Mou1, Quan Wang1, Bin Li1,2

Retreatment with Cabazitaxel in a Long‑Surviving Patient with Castration‑Resistant Prostate Cancer and Visceral Metastasis

Raquel Luque Caro, Carmen Sánchez Toro, Lucia Ochoa Vallejo

Therapy‑Induced Histopathological Changes in Breast Cancers: The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment

Shazima Sheereen1, Flora D. Lobo1, Waseemoddin Patel2, Shamama Sheereen3,
Abhishek Singh Nayyar4, Mubeen Khan5

Glioma Research in the Era of Medical Big Data

Feiyifan Wang1, Christopher J. Pirozzi2, Xuejun Li1

Transarterial Embolization for Hepatocellular Adenomas: Case Report and Literature Review

Jian‑Hong Zhong1,2, Kang Chen1, Bhavesh K. Ahir3, Qi Huang4, Ye Wu4, Cheng‑Cheng Liao1, Rong‑Rong Jia1, Bang‑De Xiang1,2, Le‑Qun Li1,2

Nicotinamide Phosphoribosyltransferase: Biology, Role in Cancer, and Novel Drug Target

Antonio Lucena‑Cacace1,2,3, Amancio Carnero1,2

Enhanced Anticancer Effect by Combination of Proteoglucan and Vitamin K3 on Bladder Cancer Cells

Michael Zhang, Kelvin Zheng, Muhammad Choudhury, John Phillips, Sensuke Konno

Molecular Insights Turning Game for Management of Ependymoma: A Review of Literature

Ajay Sasidharan, Rahul Krishnatry

IDH Gene Mutation in Glioma

Leping Liu1, Xuejun Li1,2

Challenges and Advances in the Management of Pediatric Intracranial Germ Cell Tumors: A Case Report and Literature Review

Gerard Cathal Millen1, Karen A. Manias1,2, Andrew C. Peet1,2, Jenny K. Adamski1

Assessing the Feasibility of Using Deformable Registration for Onboard Multimodality‑Based Target Localization in Radiation Therapy

Ge Ren1,2,3, Yawei Zhang1,2, Lei Ren1,2

Research Advancement in the Tumor Biomarker of Hepatocellular Carcinoma

Qing Du1, Xiaoying Ji2, Guangjing Yin3, Dengxian Wei3, Pengcheng Lin1, Yongchang Lu1,
Yugui Li3, Qiaohong Yang4, Shizhu Liu5, Jinliang Ku5, Wenbin Guan6, Yuanzhi Lu7

Novel Insights into the Role of Bacterial Gut Microbiota in Hepatocellular Carcinoma

Lei Zhang1, Guoyu Qiu2, Xiaohui Xu2, Yufeng Zhou3, Ruiming Chang4

Central Odontogenic Fibroma with Unusual Presenting Symptoms

Aanchal Tandon, Bharadwaj Bordoloi, Safia Siddiqui, Rohit Jaiswal

The Prognostic Role of Lactate in Patients Who Achieved Return of Spontaneous Circulation after Cardiac Arrest: A Systematic Review and Meta‑analysis

Dongni Ren1, Xin Wang2, Yanyang Tu1,2

Inhibitory Effect of Hyaluronidase‑4 in a Rat Spinal Cord Hemisection Model

Xipeng Wang1,2, Mitsuteru Yokoyama2, Ping Liu3

Research and Development of Anticancer Agents under the Guidance of Biomarkers

Xiaohui Xu1, Guoyu Qiu1, Lupeng Ji2, Ruiping Ma3, Zilong Dang4, Ruling Jia1, Bo Zhao1

Idiopathic Hypereosinophilic Syndrome and Disseminated Intravascular Coagulation

Mansoor C. Abdulla

Phosphorylation of BRCA1‑Associated Protein 1 as an Important Mechanism in the Evasion of Tumorigenesis: A Perspective

Guru Prasad Sharma1, Anjali Geethadevi2, Jyotsna Mishra3, G. Anupa4, Kapilesh Jadhav5,
K. S. Vikramdeo6, Deepak Parashar2

Progress in Diagnosis and Treatment of Mixed Adenoneuroendocrine Carcinoma of Biliary‑Pancreatic System

Ge Zengzheng1, Huang-Sheng Ling2, Ming-Feng Li2, Xu Xiaoyan1, Yao Kai1, Xu Tongzhen3,
Ge Zengyu4, Li Zhou5

Surface-Enhanced Raman Spectroscopy to Study the Biological Activity of Anticancer Agent

Guoyu Qiu1, Xiaohui Xu1, Lupeng Ji2, Ruiping Ma3, Zilong Dang4, Huan Yang5

Alzheimer’s Disease Susceptibility Genes in Malignant Breast Tumors

Steven Lehrer1, Peter H. Rheinstein2

OSMCC: An Online Survival Analysis Tool for Merkel Cell Carcinoma

Umair Ali Khan Saddozai1, Qiang Wang1, Xiaoxiao Sun1, Yifang Dang1, JiaJia Lv1,2, Junfang Xin1, Wan Zhu3, Yongqiang Li1, Xinying Ji1, Xiangqian Guo1

Protective Activity of Selenium against 5‑Fluorouracil‑Induced Nephrotoxicity in Rats

Elias Adikwu, Nelson Clemente Ebinyo, Beauty Tokoni Amgbare

Advances on the Components of Fibrinolytic System in Malignant Tumors

Zengzheng Ge1, Xiaoyan Xu1, Zengyu Ge2, Shaopeng Zhou3, Xiulin Li1, Kai Yao1, Lan Deng4

A Patient with Persistent Foot Swelling after Ankle Sprain: B‑Cell Lymphoblastic Lymphoma Mimicking Soft‑tissue Sarcoma

Crystal R. Montgomery‑Goecker1, Andrew A. Martin2, Charles F. Timmons3, Dinesh Rakheja3, Veena Rajaram3, Hung S. Luu3

Coenzyme Q10 and Resveratrol Abrogate Paclitaxel‑Induced Hepatotoxicity in Rats

Elias Adikwu, Nelson Clemente Ebinyo, Loritta Wasini Harris

Progress in Clinical Follow‑up Study of Dendritic Cells Combined with Cytokine‑Induced Killer for Stomach Cancer

Ling Wang1,2, Run Wan1,2, Cong Chen1,2, Ruiliang Su1,2, Yumin Li1,2

Supraclavicular Lymphadenopathy as the Initial Manifestation in Carcinoma of Cervix

Priyanka Priyaarshini1, Tapan Kumar Sahoo2

ABO Typing Error Resolution and Transfusion Support in a Case of an Acute Leukemia Patient Showing Loss of Antigen Expression

Debasish Mishra1, Gopal Krushna Ray1, Smita Mahapatra2, Pankaj Parida2

Protein Disulfide Isomerase A3: A Potential Regulatory Factor of Colon Epithelial Cells

Yang Li1, Zhenfan Huang2, Haiping Jiang3

Clinicopathological Association of p16 and its Impact on Outcome of Chemoradiation in Head‑and‑Neck Squamous Cell Cancer Patients in North‑East India

Srigopal Mohanty1, Yumkhaibam Sobita Devi2, Nithin Raj Daniel3, Dulasi Raman Ponna4,
Ph. Madhubala Devi5, Laishram Jaichand Singh2

Potential Inhibitor for 2019‑Novel Coronaviruses in Drug Development

Xiaohui Xu1, Zilong Dang2, Lei Zhang3, Lingxue Zhuang4, Wutang Jing5, Lupeng Ji6, Guoyu Qiu1

Best‑Match Blood Transfusion in Pediatric Patients with Mixed Autoantibodies

Debasish Mishra1, Dibyajyoti Sahoo1, Smita Mahapatra2, Ashutosh Panigrahi3

Characteristics and Outcome of Patients with Pheochromocytoma

Nadeema Rafiq1, Tauseef Nabi2, Sajad Ahmad Dar3, Shahnawaz Rasool4

Comparison of Histopathological Grading and Staging of Breast Cancer with p53‑Positive and Transforming Growth Factor‑Beta Receptor 2‑Negative Immunohistochemical Marker Expression Cases

Palash Kumar Mandal1, Anindya Adhikari2, Subir Biswas3, Amita Giri4, Arnab Gupta5,
Arindam Bhattacharya6

Chemical Compositions and Antiproliferative Effect of Essential Oil of Asafoetida on MCF7 Human Breast Cancer Cell Line and Female Wistar Rats

Seyyed Majid Bagheri1,2, Davood Javidmehr3, Mohammad Ghaffari1, Ehsan Ghoderti‑Shatori4

Cyclooxygenase‑2 Contributes to Mutant Epidermal Growth Factor Receptor Lung Tumorigenesis by Promoting an Immunosuppressive Environment

Mun Kyoung Kim1, Aidin Iravani2, Matthew K. Topham2,3

Potential role of CircMET as A Novel Diagnostic Biomarker of Papillary Thyroid Cancer

Yan Liu1,2,3,4#, Chen Cui1,2,3,4#, Jidong Liu1,2,3,4, Peng Lin1,2,3,4,Kai Liang1,2,3,4, Peng Su5, Xinguo Hou1,2,3,4, Chuan Wang1,2,3,4, Jinbo Liu1,2,3,4, Bo Chen6, Hong Lai1,2,3,4, Yujing Sun1,2,3,4* and Li Chen 1,2,3,4*

Cuproptosis-related Genes in Glioblastoma as Potential Therapeutic Targets

Zhiyu Xia1,2, Haotian Tian1, Lei Shu1,2, Guozhang Tang3, Zhenyu Han4, Yangchun Hu1*, Xingliang Dai1*

Cancer Diagnosis and Treatments by Porous Inorganic Nanocarriers

Jianfeng Xu1,2, Hanwen Zhang1,2, Xiaohui Song1,2, Yangong Zheng3, Qingning Li1,2,4*

Delayed (20 Years) post-surgical Esophageal Metastasis of Breast Cancer - A Case Report

Bowen Hu1#, Lingyu Du2#, Hongya Xie1, Jun Ma1, Yong Yang1*, Jie Tan2*

Subtyping of Undifferentiated Pleomorphic Sarcoma and Its Clinical Meaning

Umair Ali Khan Saddozai, Zhendong Lu, Fengling Wang, Muhammad Usman Akbar, Saadullah Khattak, Muhammad Badar, Nazeer Hussain Khan, Longxiang Xie, Yongqiang Li, Xinying Ji, Xiangqian Guo

Construction of Glioma Prognosis Model and Exploration of Related Regulatory Mechanism of Model Gene

Suxia Hu, Abdusemer Reyimu, Wubi Zhou, Xiang Wang, Ying Zheng, Xia Chen, Weiqiang Li, Jingjing Dai

ESRP2 as a Non-independent Potential Biomarker-Current Progress in Tumors

Yuting Chen, Yuzhen Rao, Zhiyu Zeng, Jiajie Luo, Chengkuan Zhao, Shuyao Zhang

Resection of Bladder Tumors at the Ureteral Orifice Using a Hook Plasma Electrode: A Case Report

Jun Li, Ziyong Wang, Qilin Wang

Structural Characterization and Bioactivity for Lycium Barbarum Polysaccharides

Jinghua Qi1,2,  Hangping Chen3,Huaqing Lin2,4,Hongyuan Chen1,2,5* and Wen Rui2,3,5,6*

The Role of IL-22 in the Prevention of Inflammatory Bowel Disease and Liver Injury

Xingli Qi1,2, Huaqing Lin2,3, Wen Rui2,3,4,5 and Hongyuan Chen1,2,3

RBM15 and YTHDF3 as Positive Prognostic Predictors in ESCC: A Bioinformatic Analysis Based on The Cancer Genome Atlas (TCGA)

Yulou Luo1, Lan Chen2, Ximing Qu3, Na Yi3, Jihua Ran4, Yan Chen3,5*

Mining and Analysis of Adverse Drug Reaction Signals Induced by Anaplastic Lymphoma Kinase-Tyrosine Kinase Inhibitors Based on the FAERS Database

Xiumin Zhang1,2#, Xinyue Lin1,3#, Siman Su1,3#, Wei He3, Yuying Huang4, Chengkuan Zhao3, Xiaoshan Chen3, Jialin Zhong3, Chong Liu3, Wang Chen3, Chengcheng Xu3, Ping Yang5, Man Zhang5, Yanli Lei5*, Shuyao Zhang1,3*

Advancements in Immunotherapy for Advanced Gastric Cancer

Min Jiang1#, Rui Zheng1#, Ling Shao1, Ning Yao2, Zhengmao Lu1*

Tumor Regression after COVID-19 Infection in Metastatic Adrenocortical Carcinoma Treated with Immune Checkpoint Blockade: A Case Report

Qiaoxin Lin1, Bin Liang1, Yangyang Li2, Ling Tian3*, Dianna Gu1*

Mining and Analysis of Adverse Events of BRAF Inhibitors Based on FDA Reporting System

Silan Peng1,2#, Danling Zheng1,3#, Yanli Lei4#, Wang Chen3, Chengkuan Zhao3, Xinyue Lin1, Xiaoshan Chen3, Wei He3, Li Li3, Qiuzhen Zhang5*, Shuyao Zhang1,3*

Malignant Phyllodes Tumor with Fever, Anemia, Hypoproteinemia: A Rare and Strange Case Report and Literature Review

Zhenghang Li1, Yuxian Wei1*

Construction of Cuproptosis-Related LncRNA Signature as a Prognostic Model Associated with Immune Microenvironment for Clear-Cell Renal Cell Carcinoma

Jiyao Yu1#, Shukai Zhang2#, Qingwen Ran3, Xuemei Li4,5,6*

PlaSciPub - Platform for Scientific Publications

Copyrights © 2021 - 2022 | Plascipub | All Rights Reserved